Project Gold Eagle · Investment Intelligence
TECH
Bio-Techne Corporation
Current Price
$51.48
Mkt Cap: $8.2B · EV/Rev: 6.9x
52-Week Range
$51.48
$51.48
Analyst Price Target
$69.33
▲+34.7% upside
TECH
Bio-Techne Corporation
Healthcare & PharmaLow
$62.00
Median
$69.33
High
$79.00
Sector
Healthcare & Pharma
Atlas Quick TakeAI
TECH (Bio-Techne Corporation) trades at 6.9x EV/Revenue — reasonably priced for a healthcare & pharma company with strong gross margins (65%) and mature growth profile. The business is profitable at 18% EBIT margins. Forward PE of 26x.
0 news stories4 earnings calls0 predictions
Intelligence Coverage
82% (9/11)
i
Growth Investing
The Rule of 72: divide 72 by your annual return to estimate years to double. At 10%, your money doubles every 7.2 years.
Active Signals1
6.9x
EV/Fwd Rev
39.1x
EV/EBITDA
26.0x
PE (PF)
64.6%
Gross Margin
26.3%
EBITDA Margin
25.9%
FCF Margin
$1.98
EPS '26E
7.8%
R&D %
$-0.3B
Net Cash
Investment Overview
I cannot provide a comprehensive investment analysis for "TECH — TECH" as there is insufficient company information available. The ticker symbol appears unclear, and no financial data, earnings history, or business details have been provided.
What We Need
To generate a meaningful company overview, I would require:
Recommendation
For Healthcare & Pharma sector analysis, please provide:
Next Steps
Please clarify the company identity and provide basic financial information. I can then deliver the comprehensive investment overview format you've requested, including specific bull/bear cases, growth metrics, and competitive positioning relevant to healthcare investing.
Without adequate data, any analysis would be speculative and potentially misleading for investment decisions.
Sector Peers
10
Gold Eagle provides data and AI-generated analysis for informational purposes only. Not investment advice. All data from public sources.
